University of Oxford-founded autoimmune disease therapy developer MiroBio has launched with support from GlaxoSmithKline subsidiary SR One.
UK-based immunotherapy developer MiroBio formally launched yesterday with £27m ($33.1m) secured in a series A round featuring pharmaceutical firm GlaxoSmithKline’s SR One unit.
The round was co-led by therapeutics-focused venture capital fund Samsara BioCapital and Oxford Sciences Innovation (OSI), University of Oxford’s VC fund. It included growth equity firm Advent Life Sciences.
Spun out of University of Oxford in October 2018, MiroBio is working on antibodies for multiple diseases that are intended to stimulate specific signals in immune cells in…
